ProCE Banner Activity

FAQs: The Expanding Role of Antibody–Drug Conjugates in Breast Cancer

Clinical Thought

In this commentary, expert faculty address questions about the emerging data on the potential expanding role of antibody–drug conjugates in the management of breast cancer.

Released: July 21, 2023

Share

Faculty

Sara A. Hurvitz

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head
Division of Hematology and Oncology
Department of Medicine
UW Medicine
Senior Vice President
Clinical Research Division, Fred Hutchinson Cancer Center
Seattle, Washington

Aditya Bardia

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine, Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research), Division of Medical Oncology
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Shanu Modi

Shanu Modi, MD

Professor of Medicine
Section Head, HER2 Breast Program
Breast Medicine Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine, Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research), Division of Medical Oncology
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Aditya Bardia, MD, MPH: consultant/advisor: Daiichi Sankyo/AstraZeneca, Foundation Medicine, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Phillips, Radius Health, Sanofi; researcher (paid to institution): Daiichi Sankyo/AstraZeneca, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Radius Health, Sanofi.

Shanu Modi, MD

Professor of Medicine
Section Head, HER2 Breast Program
Breast Medicine Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Shanu Modi, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genetech, Gilead, Seattle Genetics; researcher: AstraZeneca, Daiichi Sankyo, Genentech, Seattle Genetics.